Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination ...

Learn how long you'll likely receive Keytruda infusions, what factors can affect your treatment length, and what to expect ...

The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...

Keytruda's label does not require treatment to be stopped after two years and the number of patients receiving treatment after two years remains small, NICE noted in its guidance. Longer term ...

Keytruda, an anti-programmed death receptor ... thereby activating tumour-fighting T-cells. The label for the PD-1 inhibitor was expanded in October 2023 after the drug gained its sixth NSCLC ...

The FDA approval is based on the results of the open-label KEYNOTE-224 trial ... Overall, the results with Keytruda are very similar to that seen with BMS’ PD-1 inhibitor Opdivo (nivolumab ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

We look forward to working with the FDA to potentially bring KEYTRUDA to these patients as soon as possible.” The randomized, active-controlled, open-label KEYNOTE-689 trial evaluated Keytruda as both ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes. Among patients with unresectable, non-metastatic ...

Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s Keytruda-challenging ivonescimab in combination with several of its antibody-drug conjugates (ADCs).